Polyurethane composition for preparing medical dressing

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a composition for preparing a polyurethane foam dressing which contains the ingredients in the composition in the following ratio, weight fractions: low-molecular polyesterpolyol No. 1 - 75-90, low-molecular polyesterpolyol No. 2 - 10-25, water - 1.0-2, a foaming agent - 1.0-3.0, an urethane formation catalyst - 0.05-0.3, a co-catalyst - 0.05-0, a foam regulator - 2.0-7.5, a bactericidal additive - 1.0-1.2, aromatic diisocyanate - 30-60.

EFFECT: requiring no additional fixation, the medical dressing is easily applied on a wound surface regardless of a configuration and a size of the injured area, and is formed directly on the patient's wound, providing a sterile surface and an anaesthetic effect; its open porous structure absorbs various wound discharges.

3 tbl

 

The invention relates to the field of production of medical dressings, namely the receipt of such materials based on polymer compositions.

The invention can most effectively be used in traumatology and surgery to obtain semifictional viscoelastic polyurethane foam dressing designed for the closure of wounds of different origin. Medical bandage is easy to apply on the wound surface, regardless of the configuration and size of the affected area and is formed directly on a wound of a patient, providing a sterile cover and the effect of anesthesia, and due to its open porous structure absorbs a different kind of discharge from the wounds of the victim.

Known composition (patent RF 2245164, IPC 7 A61L 15/26, A61F 13/15. Medical bandage. // EN BIPM 3, 27.01.2005. - S), selected as analog, including oligoarticular based on propylene oxide and ethylene oxide, the catalyst retinoblastoma and isocyanate component and wherein the polyol as one component contains the activation additive, which includes the chain extension of the polyurethane; as a polyol as one component using macromolecular simple polyol; an isocyanate component contains oligomerization and an excess of a mixture of 4,4'- and 2,4'-isomers of diphenylmethanediisocyanate has a content of isocyanate groups is 26.0-29.5 wt.% in the following ratio of components in mass:

High-molecular oligoarticular100
Water2,0-4,0
Catalyst retinoblastoma0,4-2,0
Pootkryvali0,2-1,5
Periotoneal0,2-1,5
Isocyanate component30-60

However, the bandage has a number of disadvantages. Temperature limit its use is limited from 18 to 40C, so if the temperature drops, it requires additional heating, which causes some inconvenience. Absorption capacity of the dressing decreases when the temperature drops below 18C, as the bandage is reduced in volume and the number of open pores is reduced. The cost of dressing is quite high due to the use of a significant number of compounds included in its composition.

Known composition (Patent RU 2379060 C2, IPC A61L 15/26 (2006.01), A61F 13/15 (2006.01), selected as a prototype, including simple oligoarticular based on propylene oxide and ethylene oxide, water, activator retinoblastoma, isocyanate component, consisting of with whom thou isomers of diphenylmethanediisocyanate with the content of isocyanate groups 26,0-32 wt.%, activation supplements pootkryvali, penitences, blowing agent, and characterized in that the polyol as one component contains high polyetherpolyols, foaming agent and additive activation, which includes the chain extension of the polyurethane, in the following ratio of components in mass:

High-molecular oligoarticular100
Water2,0-4,0
the expander2,0-4,0
activator retinoblastoma0,05-0,4
the chain extension0,2-1,5
pootkryvali0,2-1,5
periotoneal0,2-1,5
isocyanate component30-60

Composition-the prototype has the following disadvantages.

To create dressing as the foaming agent used flammable components (n-pentane, isopentane, Methylcyclopentane etc)that entail strict safety as in the production of component "A", the AK and when this component is used in practice when applying bandages.

Manufacturers of polymeric MDI (in particular the company "Huntsman", diphenylmethanediisocyanate ("Suprasec 2456") which is used on the prototype) found that the lower the ambient temperature is below 10C leads to crystallization and reduced activity of the polyisocyanate component. In this regard, necessary or heating component or increase the time of its mixing with the polyol as one of the components (mixing 60 seconds on the prototype), or the application of a sufficient amount of active catalyst or chain extension (using alkanolamine the prototype to a full-fledged foaming process. When the temperature drops below 10C, the absorption ability of the dressings is limited by the amount of the resulting polymer mass, it becomes significantly less number of open pores is reduced.

In the prototype there are no indicators gel dressings, characterizing its adsorption properties that affect therapeutic effectiveness of medical material.

The cost of bandages, high enough as to make it apply 9 components, the concentration of some of them is quite high.

The technical purpose of this invention is to provide a viscoelastic polyurethane foam material; increasing the absorption properties of polychemotherapy by increasing the number of open pores; elimination of pain in patients by identifying the optimum temperature of reaction by reducing the time of gel formation and structuring of dressing, using a new generation of ozone-friendly blowing agents having flame resistant properties; increased biocide (including antimicrobial and bactericidal properties of the material by introducing into the polymer matrix bactericidal additive; a decrease in the concentration and composition of chemical components, including the extension of the chains, resulting in a reduction in the cost of the target product.

The technical result consists in the creation of a viscoelastic polyurethane foam dressings high performance of therapeutic action on the basis of two-component politicisation system by migration of polymerization and partial polycondensation components, as well as in the selection of their specific composition and content.

The problem is solved in that the composition consists of a polyol as one component (component "A") on the basis of a simple mixture of low molecular weight polyesters (IPPS) based on propylene oxide with glycerol, propylene oxide with ethylene oxide, and oxide of glycerol and sucrose; water, catalyst retinoblastoma and co-catalyst, flame-resistant a blowing agent, preregulator, bactericide the second additive, as well as isocyanate component (component B)consisting of a mixture of isomers diphenylmethanediisocyanate with the content of isocyanate groups 26,0-32 wt.%, in the following ratio of components in mass:

Component "A":

low-molecular polyetherpolyols No. 180-90
low-molecular polyetherpolyols No. 210-20
water1,0-2,0
foaming agent1,0-3,0
catalyst retinoblastoma0,05-0,3
the co-catalyst0,05-0,3
foam controller2,0-7,5
bactericidal additive0,8-1,2

Component "B":

aromatic diisocyanate35-65

As the low molecular weight polyether polyols (#1 and # 2) with terminal hydroxyl groups use polyethers based on propylene oxide with glycerine and propylene oxide with oxide-ethyl is a, and oxide of glycerol and sucrose. In particular, it is possible to use polyols produced by Russian manufacturers under the name "PROPOL 1055", "PROPOL 1010", "PROPOL 490", "Laprol 3003" as well as imported analogues firms "Bayer", "Huntsman", "Fushun Jiahua Polyurethane" or "Jiangsu Zhongsham chemical with standard molecular mass polyols ranges for No. 1: 1000-3000 and No. 2: 400-600, the use of which is conditioned by the specificity of the reactions occurring in the final product.

To accelerate the process of formation of the polyurethane foam in the component "A", in addition to the water prior to introducing the catalyst retinoblastoma based on tertiary amines and co-catalyst reaction - ORGANOTIN compound in the ratio of 1:0.8 to 1. As the catalyst used, for example, dimethylcyclohexylamine (DMCHA), and as a co-catalyst - dibutylthiourea tin (DBDLO)produced by firms "Air Products Chemicals", "Evonik Industries", "Huntsman" or "Momentiv". As a catalyst can be used as a 33% solution of triethylenediamine in dipropyleneglycol (Dabco 33 LV - trade name of the manufacturer "Air Products Chemicals"). The ratio of catalyst and co-catalyst depends on the temperature and usage bandages and the average calculated for a temperature of not lower than 10C, because the storage of the second component (component B) at a temperature below 10C can lead to crystallizer is and diphenylmethanediisocyanate. Lowering the temperature to 5C for the component "A" only leads to the increase of viscosity.

As the foam controller uses the standard silicone stabilizers (preregulatory open porosity) on the basis of organomodified polysiloxane, in particular stabilizers "Tegastab 8734 LF2", "Tegastab 8726 LF" or "Tegastab 8629"stabilizing actions which increase in the order they are presented, by Evonik Industries, or stabilizers for the regulation of the open porosity of the foam firm Air Products Chemicals".

To speed up the process of foaming and reduce the temperature of the structuring headbands and reduce pain in patients by reducing temperature using a mixture of fluorine-containing reactants, in particular a mixture of 1,1,1,3,3-pentafluorobutane and 1,1,1,2,3,3,3-Heptafluoropropane with a ratio of 93:7 to 87:13. This ratio foaming agents allows you to adjust the boiling point of the mixture and thereby define their relationship in the polyol as one component of "A" at different ambient temperatures. With a ratio of 93:7 boiling point of the mixture is 30C and the change in the proportion of the content of these reagents is reduced to 24C at 87:13, respectively. At this rate the components of the mixture is also fireproof and does not require additional security measures p and applying a bandage to the wound, what is needed, for example, when using pentane or its isomers as blowing agent upon receipt of a bandage similar actions.

As bactericidal additives used concentrate colloidal solution of silver nanoparticles, iodophore or solution Miramistin, produced by Russian manufacturers. The additive has a positive effect on the healing process of wounds, with a pronounced therapeutic effect at a concentration of not less than 0.8 but not more than 1.2, because the above is already possible overdose.

As component "B" use polymer diphenylmethanediisocyanate, in particular "Suprasec 2456" company "Huntsman" with a content of isocyanate groups 29,7. This polyisocyanate is prepolymer with the modified reactivity-based diphenylmethanediisocyanate (DHS) with the content of some of the isocyanate with high functionality. The structure of such polyisocyanates can reduce the exothermic effect of the reaction of formation of foam in the wound of the victim.

Composition for medical dressings prepared from two components "a" and "B", pre-prepared first from a mixture of all the required components, namely the polyol, water, catalyst and co-catalyst retinoblastoma, a blowing agent, preregulator, bactericide the second additive and/or additive sorption, as follows:

components "a" and "B" are mixed immediately prior to use in a special two-component plastic propagate in the ratio a:B=1:0,50-0,65, after removing the wall that separates the components "a" and "B" (option in practice) or in a plastic Cup (under laboratory conditions) until a color change composition from brown to light yellow within 10-20 seconds (prototype 50-60 sec);

- open the package, pour the contents on the wound surface and level the edges using a spatula or other tool (in practice). Or poured on a smooth plastic surface (in laboratory conditions), which is applied to native plasma (or water), which podkrucheno indicator methylene blue, imitating the wound;

- for 3-12 minutes depending on the ambient temperature and the temperature of the components of the polyurethane foam hardens on the wound (or polyethylene) in the form of a porous sponge, providing wound closure, significantly reduce pain in a patient due to the low (up 32-41C) temperature structure of the foam and contributing to the outflow of secretions from the wound.

Examples of specific compounds of the claimed composition and properties of the obtained bands are presented in tables 1-2.

The number of components was chosen t is thus, to ensure optimum foaming and curing of the compositions, and to obtain the necessary physical and mechanical properties and structure of the resulting polyurethane foam. It can be seen from the specific illustrated example.

Medical dressings-based polyurethane foam (PUF) of the composition represented by the example of formulation No. 3 (table 1).

Component "A" is prepared by successively mixing the starting components in the following order: 80 mass low molecular weight polyetherpolyols No. 1 (PROPOL 1055) add 20 mass low molecular weight polyetherpolyols PROPOL 490 (both manufactured. JSC "Plant polyols"), 5 mass of foam controller Tegastab 8734 LF2 ("Evonik Industries"), 0,3 mass catalyst Tegoamin DMCHA ("Evonik Industries) and 0.3 mass co-catalyst DBDLO ("Air Products Chemicals), and 1 mass water. This mixture is stirred using a high speed stirrer (speed, which ranges from 1,000 to 1,500 rpm) for 20-30 seconds, then add 3 parts by weight of a blowing agent mixture of pentafluorobutane and Heptafluoropropane in the ratio of 93:7 and reducing the number of revolutions of the stirrer to 1000, stirred the mixture for 10-15 seconds. Next enter 0,8 mass bactericidal additive Ag-Bion-2 (projectors. The Institute for nanotechnologies) and continue mixing for another 10-20 seconds. Received component "And" thermostatic at room tempera what ur in for hours. Next, prepare the foam composition consisting of previously prepared component and polyisocyanate component "B". Dosing of the components is carried out in a plastic bag (container) with a capacity of 250-300 ml as component "B" use polymer diphenylmethanediisocyanate, in particular "Suprasec 2456" company "Huntsman" with a content of isocyanate groups 29,7. 100 mass component "And" take 59,2 mass component "B". Mixing is carried out in the bag (container), intensively rubbing manual components to each other within 10-20 seconds. The mixed composition is immediately applied to the simulated wound surface. After a few minutes, the applied composition is transformed into a porous sponge is firmly held on the surface of the wound and clearly follows the contour of the body part on which it has been applied. Within the first 3 minutes, the sponge is characterized by sufficient stickiness, which completely disappears after 5-10 minutes after application. Received poliuretanowa bandage has a fine heterogeneous structure without shells, with small inclusions of larger cells and is characterized by the following indicators technology preview: start time of 40 seconds, the gelation time of 145 seconds, the growth of the foam - 175 seconds, the tack-free time - 5 minutes, the temperature during formation of the foam was 37C. the foam bandage after which formirovaniya structure has a porosity of 68%, apparent density of 95 kg/m3, a sorptive capacity for water - 8,05 g/g, Density of 5.2 mg/cm2hour, water for 24 hours - 68%.

Examples of other compounds presented in table 1 are similar and differ only in the mass content of the original substance, and formed by mixing the composition with the polyisocyanate component of the polyurethane foam is characterized by different technological and physico-mechanical properties within the stated ratios.

Thus, the optimum composition is to obtain a medical polymer material comprising a mixture of polyether polyols based on propylene oxide with glycerine and propylene oxide with ethylene oxide, and oxide of glycerol and sucrose, the catalyst and co-catalyst retinoblastoma, foam controller and polymeric diisocyanate; characterized in that as the use of polyether polyols of low molecular weight polyols with a molecular weight of 400-600 and 1000-3000, the composition contains bactericidal additive, and as a blowing agent is a mixture of 1,1,1,3,3-pentafluorobutane and 1,1,1,2,3,3,3-Heptafluoropropane (from 93:7 to 87:13) and does not contain a chain extension when the following ratio of components in mass:

Component "A"

80-90
low-molecular polyetherpolyols No. 1
low-molecular polyetherpolyols No. 210-20
water1,0-2,0
foaming agent
(a mixture of 1,1,1,3,3-pentafluorobutane
and 1,1,1,2,3,3,3-Heptafluoropropane
(from 93:7 to 87:13))1,0-3,0
catalyst retinoblastoma0,05-0,3
the co-catalyst0,05-0,3
foam controller2,0-7,5
bactericidal additive0,8-1,2

Component "B":

aromatic diisocyanate35-65

The data in table 1, 2, and their comparison with the data of the prototype in table 3 showed that the claimed invention solved the following technical tasks:

- increase the absorption properties of the material obtained by increasing the number of open pores (above 70%), which allows to increase sorcio the ing the capacity of the bandage;

- determination of the optimal temperature of the reaction (about 39.5C) by reducing the time of gel formation and structuring of the bandage through the use of the declared blowing agents, which in turn leads to the elimination of pain in patients;

- increased biocide (including antimicrobial and bactericidal properties of the material by introducing into the polymer matrix bactericidal additive;

the decrease in the concentration and composition of chemical components (up to 7 components), resulting in a reduction in the cost of the target product;

- ensuring the sealing of the wound by sticking to healthy skin and a high congruence to the relief of a wound;

facilitation of wound care through a single blending a polyurethane coating.

Table No. 3
The composition of the prototype, the technological parameters of the sample and the properties of the obtained materials
Description polyol as one of the componentThe composition of the prototype (mass. parts), # example
1 2345
The high molecular polyol100100100100100
33% solution of triethylenediamine0,5250,5250,5250,050,05
Dibutil-tin-diluent0000,050,05
water3,153,153,153,153,15
The chain extension0,2730,2730,2730,2730,273
Pootkryvali0,5250,5250,5250,5250,525
Periotoneal0,5250,5250,5250,5250,525
N-pentane00300
The amount of polyisocyanate component, MASC 100 concerns polyol33332828,528,2
Parameters technology preview
The time of mixing the components with50-6050-6050-6050-6050-60
The start time2580252122
The growth time foam140180115109120
2170151512
The temperature of the composition during formation of the foam, C5040485042
Feature foam
Apparent density, kg/m360100485144

The polyurethane composition to obtain a medical dressing comprising a mixture of polyether polyols, catalyst and co-catalyst retinoblastoma, foaming agent, foam controller and polymeric diisocyanate, characterized in that the polyether polyols # 1 and # 2 use low molecular weight polyols with molecular masses, respectively 1000-3000 and 400-600, and as a blowing agent is a mixture of 1,1,1,3,3-pentafluorobutane and 1,1,1,2,3,3,3-Heptafluoropropane in a ratio of 93:7 to 87:13, and the composition additionally contains antibacterial additive in the following ratio of components, parts by weight:

Component "A"
low-molecular polyetherpolyols No. 180-90
low-molecular polyetherpolyols No. 210-20
water1,0-2,0
foaming agent (a mixture of 1,1,1,3,3-pentafluorobutane
and 1,1,1,2,3,3,3-Heptafluoropropane)1,0-3,0
catalyst retinoblastoma0,05-0,3
the co-catalyst0,05-0,3
foam controller2,0-7,5
bactericidal additive0,8-1,2
Component "B":
aromatic diisocyanate35-65



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to method of obtaining medical napkin for treatment of wounds and burns. In method of obtaining medical napkin, which includes carrying out textile material padding in solution of medication with the following drying in the air, padding is carried out in solution of sodium alginate polysaccharide with content of 18-22% dimexide, and after drying by method of textile printing water solution of polymer composition containing 18-22% of urea, 5-7% of sodium alginate is applied on textile carrier, with following drying of processed material in the air. Method makes it possible to considerably increase concentration of medication in napkin, considerably extend spectrum of applied medications, including by low-soluble, as it does not require presence of functional groups in medication for immobilisation on functional groups of fibre.

EFFECT: method is simpler in realisation, less durative, does not require additional processing of textile material, ie more manufacturable and economical.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to a therapeutic plaster which can provide injured skin or open wounds with an active substance promoting faster or improved wound healing. The plaster shows the new design features which particularly enable drug substances containing proteins or peptides, e.g. erythropoietin (EPO) to exhibit their wound healing and stimulating action ensured by active substance release from the plaster which is not subject to substantial inactivation by the substances contained in wound secretion, and is not metabolised.

EFFECT: making the therapeutic plaster which can provide injured skin or open wounds with an active substance promoting faster or improved wound healing.

37 cl, 1 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a biodegradable plaster containing at least one bioadhesive layer, and at least one non-bioadhesive layer with the bioadhesive layer containing at least one polyarphon dispersion, and at least one bioadhesive polymer with the polyarphon dispersion containing at least one pharmacologically active substance.

EFFECT: biodegradable plaster can deliver drugs, including poorly water soluble ones.

21 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a bandage for pain region processing. The bandage provides cooling and delivery of therapeutic formulations to this region. The bandage comprises a bearing carrier, an interpenetrating network of gel-type dope of polyvinyl alcohol and a cross-linking agent wherein the interpenetrating network is located in the bearing carrier, and at least one additional therapeutic agent.

EFFECT: bandage may be applicable many times on various body parts.

21 cl, 4 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a haemostatic device for blood coagulation improvement which contains a gauze base, a clay material located thereon, and also polyol, such as glycerol or similar placed on the gauze base for binding the clay material. The device for bleeding wound management comprises at least a portion of the clay material contacting to blood flowing from the wound to cause coagulation. A dressing applicable on the bleeding wound for blood coagulation improvement comprises a flexible base and a gauze base located thereon. The gauze base comprises the clay material and polyol. Ahaemostatic sponge also contains a gauze basis and a disperse system of the haemostatic material and polyol on the first base surface. The invention also refers to N-substituted monomers and polymers, methods for producing such monomers and polymers and to methods for using for various medical purposes, e.g. in medical devices. In the preferential versions, a medical device represents a stent.

EFFECT: haemostatic device improves blood coagulation.

43 cl, 1 tbl, 9 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, namely to application of copolymer of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propansulfonic acid salt and 2-hydroxyethyl ester of propenoic acid as agent for release of active substance in composition for bandage. Invention also relates to bandages, containing at least one adipose substance and/or elastomeric matrix and at least one active substance, which also contain said copolymer.

EFFECT: active agent, included into bandage composition, is not toxic for cells, in particular, fibroblasts, and does not influence properties of cohesion, absorption or adhesion of compositions.

25 cl, 1 dwg, 10 tbl, 18 ex

Transdermal plaster // 2445123

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly pharmaceutical preparations, namely: plasters for transdermal application. What is described is a transdermal plaster representing a matrix system and comprising a lining layer, a matrix layer and a lightproof protective coating in the following proportions: mexidol substance (4.59 wt %), propylene glycol 10.32 wt %, PVP K90 (Plasdone K90) 10.09 wt %, 95% ethanol 75.0 wt %. The plaster aims at the transdermal introduction of mexidol. A plaster area is 25 cm2.

EFFECT: plaster is used for treating and preventing chronic diseases, allows avoiding the problems related to oral administration, improves patient compliance; it is applicable in children and elderly persons, suitable for purposes of combination therapy.

5 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery, and is intended for pathogenically substantiated treatment of wounds of various etiology at the first stage of wound process. Described is application in wound covering of single complex from perforated cellulose Acetobacter xylinum and biologically active ingredients, which have therapeutic effect. Into wound covering included are complex fullerene C60/Tween-80 (antioxidant), antimicrobial component, antienzymatic and haemostatic component, necrolytic component.

EFFECT: due to wet medium supplied are optimal for wound reparation conditions, and due to application of perforated bacterial cellulose covering is vapour- and air permeable.

4 cl, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to transdermal therapeutic system, which contains, at least, one easily volatile and/or thermolabile biologically active substance and/or auxiliary substance, which can be obtained by limiting on each other of, at least, three components, namely, polymer matrix layer, acceptor layer, absorbing with high speed biologically active substance and/or auxiliary substance, as well as donor-layer, which by the moment of manufacturing contains volatile and/or thermolabile biologically active substance and/or auxiliary substance. During or immediately after lamination process, donor-layer by means of migration of volatile and/or thermolabile substances combines with acceptor layer.

EFFECT: transdermal therapeutic system ensures improved gastrointestinal tolerance.

12 cl, 1 tbl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically to dressing used for closure and treatment of burns, wounds of various aetiology, trophic ulcers, decubitus ulcers, etc. What is described is a bandage in which three components are used: a wound-facing nontraumatic textile layer with antiseptic butole in the concentration 0.05 mg/cm2 to 1.0 mg/cm2 in a therapeutic layer which is coated with a replaceable sorptive layer made of a nonwoven fabric and providing sorption power of the bandage within 15 g/g and 10 g/g once changed. The replaceable sorptive layer is fixed between the therapeutic and sorptive layers by means of an adhesive frame which is a third component, e.g. made of a nonwoven fabric 0.1-0.5 mm thick and 6.0-10.0 mm wide; both surfaces of the frame are coated with a therapeutic adhesive, and an outer size of the framework is equal to a length and a width of the therapeutic layer. The therapeutic layer additionally contains drugs of haemostatic, anaesthetising, antioxidant and/or wound healing action.

EFFECT: production of the sustained-action bandage with extended spectrum of antimicrobial action, improved antimicrobial activity and higher sorption power.

2 cl, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to the chemistry of foamed polyurethanes, particularly a polyurethane system for making elastic articles, preferably for medical purposes, for example, orthopaedic articles, technical parameters of which have improved sanitary properties which meet their operating requirements. The present invention can also be used to make polyurethane bandages. The polyurethane system for making articles with improved sanitary properties contains compositions based on a polyol compound A, an isocyanate compound B and a mineral agent C, which is dispersed in polyol compound A. The isocyanate compound B used is prepolymers of methylene diphenyl diisocyanates MDI. The mineral agent C used is a mixture of bentonite nanopowders which are intercalated with silver ions Ag+ and cerium ions Ce3+.

EFFECT: improved sanitary properties of the obtained elastic articles, with regard to both inhibiting growth of microorganisms and reducing gas release of volatile toxic organic compounds.

9 cl, 2 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, in particular, to polymer-based dressings, and can be applied in surgery for closing wounds of various etiology. Described is gel-like coating from elastic foam-polyurethane, which consists of polyol component including highly molecular simple oligoetherpolyol on the basis of propylene and ethylene oxide, water, urethane-formation activator, isocyanate component, which includes mixture of diphenylmethane diisocyanate isomers, activation additive, consisting of polyurethane chain extender, foam-opener, foam-hardener, in activation additive additionally introduced is foaming agent, as activator, used is "mixture of tertiary amines and tin-organic compounds with ratio 1:1 (wt fr.)", isocyanate component with content of isocyanate groups 26.0-32 wt % with the following ratio of ingredients in composition, wt fr.: highly molecular oligoetherpolyol - 100, water - 2.0-4.0, foaming agent - 2.0-4.0, urethane-formation catalyst (mixture of tertiary amines and tin-organic compounds with ratio 1:1 (wt fr.)), - 0.05-0.4, chain extender - 0.2-1.5, foam-opener - 0.2-1.5, foam-hardener - 0.2-1, isocyanate component with content of isocyanate groups 26.0-32 wt % - 30-60, and into composition of polyol component introduced are boehmite nanoparticles with size from 10 to 50 nm with its weight to 10% of polyol component weight.

EFFECT: improvement of sorbing properties of polyurethane coating due to strengthening capillary walls, reduction of their radius and extension of capillary system, which makes it possible to obtain sorbing volume of coating material exceeding 90%.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. Described is a multilayer bandage of at least the following structure: nonwoven web 1 which shall contact with a wound, and a membrane 3 which is water-proof and comprises water-insoluble polymer.

EFFECT: multilayer bandage is not adhered to wound and thereby do not interpenetrate with it.

15 cl, 6 dwg

FIELD: medicine.

SUBSTANCE: invention concerns medicine, more specifically to a new method for making a sheet material with interpenetrating polymer networks (IPN). In comparison with the common methods, the offered method shows such advantages as, e.g. a) one-pass making capability for sheet material with IPN, b) the absence of the second liquid polymer coating used as a glue, c) the absence of solvents or other auxiliary materials, d) producibility of the material in the furnace during the required time without elongation, e) higher material traverse and f) applicability of the coating only on one side of a carrier body.

EFFECT: invention concerns particularly making such sheet material and its combination with a protective material to be used as a dressing and as an adhesive plaster.

26 cl, 7 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely dressings with polymer compositions and can be used in surgery and traumatology for various wound closing. A medical dressing formed on a wound directly ensures its full sterile closing, provides anaesthetic effect, primary disinfection and exudate absorption from the wound of a patient and medical staff and does not require additional fixation. The dressing consists of a polyol component containing high-molecular simple oligoesterpolyol based on propylene oxide and ethylene oxide, water, an urethane formation activator, an isocyanate component containing mixed isomers of dimethylmethane diisocyanate, an activation additive consisting of the extension of polyurethane chain, a foam opener. The activation additive also contains a foaming agent. The activator is mixed amines and organotin compounds. The isocyanate component has the isocyanate group content 26.0-32 wt % in the following ratio in the composition, weight fractions: high-molecular oligoesterpolyol - 100, water - 2.0-4.0, the foaming agent - 2.0-4.0, the urethane formation activator - 0.05-0.4, the chain extension - 0.2-1.5, the foam opener - 0.2-1.5, the foam hardener - 0.2-1.5, the isocyanate component - 30-60.

EFFECT: extended temperature range of dressing use to 5C, elimination of collateral pain sensations in patients (reduced temperature of reaction), further improvement of absorption properties and reduced cost price of the dressing.

7 ex

FIELD: medicine.

SUBSTANCE: present invention concerns medicine, specifically an absorbent product, such as a diaper, diaper panties, sanitary towel, sanitary tissue, incontinence appliance or similar, containing as specified: a fluid-permeable coat, optionally sub-layer of cloth or porous material, optionally an absorbent layer and a fluid impenetrable coat, differing that at least one part of said absorbent towel contains polymer which is hydrophilic if dry, however shows lowered hydrophilic behaviour after humidifying; and also concerns the related fluid-permeable and impenetrable coat and cloth or porous material.

EFFECT: absorbent product shows optimum hydrophilic/hydrophobic properties to ensure good fluid distribution after humidifying.

16 cl

Bandaging material // 2326698

FIELD: medicine.

SUBSTANCE: described bandaging material contains non-volatile silicone fluid mixed with colloidal silicon dioxide, volatile solvent and silicone elastomer. Material is improved composition applied for specific tissue area amenable to pathogenic infections and/or scarring.

EFFECT: has improved composition.

33 cl, 4 tbl, 7 ex

FIELD: biotechnology, microbiology, medicine.

SUBSTANCE: invention relates to novel probiotic strains of lactobacilli: Lactobacillus acidophilus DSM 14869, Lactobacillus paracasei DSM 14870, Lactobacillus acidophilus DSM 15525, Lactobacillus plantarum DSM 15524, Lactobacillus sp. DSM 11526 and the strain Lactobacillus sp. DSM 15527. Strains shows similar favorable properties used separately or in combination as probiotics or in common with prebiotic as symbiotic. Also, invention relates to pharmaceutical compositions, dairy foodstuffs, functional foodstuffs, nutrient supplements and agents for personal hygiene comprising strains in separately or in combination, and to using strain for prophylaxis or treatment of vaginal infections, urogenital infections and gastrointestinal diseases.

EFFECT: valuable properties of strains.

43 cl, 12 ex

FIELD: medicine.

SUBSTANCE: the present composition includes nonvolatile, a silicone, fluid substance in the mixture with finely divided silicon dioxide and antibacterial active substance. Pharmaceutically active substance is a nondecomposing one and manifests physical stability in the composition.

EFFECT: higher efficiency.

31 cl, 5 ex, 2 tbl

FIELD: medicine, special additives.

SUBSTANCE: invention relates to hygroscopic additive that represents particles of hygroscopic additive containing particles of hygroscopic resin (α) and additive improving penetrability for liquid (β) wherein particles of hygroscopic resin (α) represent particles of cross-linked polymer formed from a monomer comprising acrylic acid and/or its salt and subjected for treatment resulting to formation of cross-links on its surface. Particles of the proposed hygroscopic additive show average-mass diameter (D50) in the range from 234 to 394 mcm, logarithm standard deviation (σξ) for distribution of particles by sizes in the range from 0.25 to 0.45, absorbing capacity without loading 15 g/g, not less, and the level of the water-extractive component content 15 wt.-%, not above, and, except for, the level of the additive content improving penetrability of liquids (β) in the range from 0.01 to 5 mass parts per 100 mass parts of particles of hygroscopic resin (α). Proposed hygroscopic additive combines exploitation indices describing both capillary absorption strength and penetrability for a liquid.

EFFECT: improved and valuable properties of additive.

8 cl, 7 dwg, 29 ex

FIELD: medicine.

SUBSTANCE: invention relates to sanitary pad, which includes protective layer, barrier layer, located between them absorbing core, as well as first and second relief patterns, which include first and second distantly located parts. Each of first and second parts of first and second relief patterns includes multitude of channels, with each of channel running from one side of longitudinally extending central line to the opposite side of longitudinally extended central line. Each of channels crosses, at least, other channel at non-right angle to it, and each of channels passes through longitudinally extended central line at non-right angle to it. Each of first and second parts of second relief pattern is limited with multitude of interconnected channels, with channels limiting multitude of body-facing projections. Between first and second parts of second relief pattern relief-free zone is located.

EFFECT: invention ensures efficient absorption of flowing medium due to movement of flowing medium along pad channels in several directions in pad width and length to accelerate its absorption, as well as prevention of side leakage of flowing medium.

19 cl, 1 ex, 1 tbl, 6 dwg

Up!